

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal (STA)

Vedolizumab for treating moderately to severely active ulcerative colitis  
[ID691]

## Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Takeda (vedolizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Bowel Cancer UK</li> <li>• Colostomy Association</li> <li>• Crohn's and Colitis UK</li> <li>• Equalities National Council</li> <li>• Ileostomy and Internal Pouch Support Group</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Ostomy Lifestyle</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Ulcerative Colitis UK</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Society of Gastroenterology</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturer</u></p> <ul style="list-style-type: none"> <li>• AbbieVie (adalimumab)</li> <li>• Accord Healthcare (tacrolimus)</li> <li>• Actavis (azathioprine, mesalazine, prednisolone, sulfasalazine)</li> <li>• Alliance Pharmaceuticals (prednisolone)</li> <li>• Almirall (balsalazide)</li> <li>• Arrow Generics (azathioprine)</li> <li>• Aspen (azathioprine, mercaptopurine)</li> <li>• Astellas Pharma (tacrolimus)</li> <li>• AstraZeneca (budesonide)</li> <li>• Auden McKenzie (hydrocortisone)</li> <li>• Bayer (prednisolone)Chiesi (beclometasone)</li> <li>• Dexcel-Pharma (ciclosporin, tacrolimus)</li> <li>• Dr. Falk Pharma (budesonide, mesalazine)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Thanet CCG</li> <li>• NHS South Kent Coast CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Ferring Pharmaceuticals (mesalazine)</li> <li>• Intrapharm Laboratories (prednisolone)</li> <li>• LPC Medical (prednisolone)</li> <li>• Meda Pharmaceuticals (hydrocortisone)</li> <li>• Merck Sharp and Dohme (golimumab, infliximab)</li> <li>• Metwest Pharmaceuticals (prednisolone)</li> <li>• Mylan (azathioprine, ciclosporin, sulfasalazine, tacrolimus)</li> <li>• Novartis Pharmaceuticals (ciclosporin)</li> <li>• Pfizer (hydrocortisone, sulfasalazine)</li> <li>• Ranbaxy (sulfasalazine)</li> <li>• Rosemont Pharmaceuticals (sulfasalazine)</li> <li>• Sandoz (azathioprine, mesalazine, tacrolimus)</li> <li>• Sanofi (hydrocortisone)</li> <li>• Shire Pharmaceuticals (hydrocortisone, mesalazine)</li> <li>• Teva (azathioprine, ciclosporin, hydrocortisone, mesalazine, prednisolone, sulfasalazine, tacrolimus)</li> <li>• Tillotts Pharma (mesalazine)</li> <li>• UCB Pharma (olsalazine)</li> <li>• Wockhardt (prednisolone)</li> <li>• Zentiva (prednisolone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Health Research Authority</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> <li>• School of Health &amp; Related Research Sheffield (SchARR)</li> </ul> <p><u>Associated Guideline groups</u></p>

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.